High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: Evidence for subtype-specific rather than strain-specific neutralizing activity

Journal of General Virology

Volumn 91, Issue 1, 2010, Pages 250-258

  van Gils, Marit J ^a   Edo Matas, Diana ^a   Schweighardt, Becky ^b   Wrin, Terri ^b   Shuitemaker, Hanneke ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; DRUG EFFICACY; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IC 50; IMMUNE RESPONSE; MALE; PHENOTYPE; PRIORITY JOURNAL; SEROTYPE; SERUM VIRUS NEUTRALIZATION; VIRUS DETECTION; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS TITRATION; VIRUS VIRULENCE;

ANTIBODIES, NEUTRALIZING; CROSS REACTIONS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; NETHERLANDS; NEUTRALIZATION TESTS;

CERCOPITHECINE HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 73149116824     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.015693-0     Document Type: Article

References (40)

1. Binley, J. M., Wrin, T., Korber, B., Zwick, M. B., Wang, M., Chappey, C., Stiegler, G., Kunert, R., Zolla-Pazner, S. & other authors (2004). Comprehensive cross-clade neutralization analysis of a panel of antihuman immunodeficiency virus type 1 monoclonal antibodies. J Virol 78, 13232-13252.
2. Brown, B. K., Wieczorek, L., Sanders-Buell, E., Rosa, B. A., Robb, M. L., Birx, D. L., Michael, N. L., McCutchan, F. E. & Polonis, V. R. (2008). Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 375, 529-538.
3. Bunnik, E. M., Pisas, L., van Nuenen, A. C. & Schuitemaker, H. (2008). Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 82, 7932-7941.
4. Burton, D. R., Desrosiers, R. C., Doms, R. W., Koff, W. C., Kwong, P. D., Moore, J. P., Nabel, G. J., Sodroski, J., Wilson, I. A. & other authors (2004). HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5, 233-236.
5. Conley, A. J., Gorny, M. K., Kessler, J. A., Boots, L. J., Ossorio-Castro, M., Koenig, S., Lineberger, D. W., Emini, E. A., Williams, C. & other authors (1994). Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol 68, 6994-7000.
6. Dhillon, A. K., Donners, H., Pantophlet, R., Johnson, W. E., Decker, J. M., Shaw, G. M., Lee, F. H., Richman, D. D., Doms, R. W. & other authors (2007). Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 81, 6548-6562.
7. Doria-Rose, N. A., Klein, R. M., Manion, M. M., O'Dell, S., Phogat, A., Chakrabarti, B., Hallahan, C. W., Migueles, S. A., Wrammert, J. & other authors (2009). Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83, 188-199.
8. Gaschen, B., Taylor, J., Yusim, K., Foley, B., Gao, F., Lang, D., Novitsky, V., Haynes, B., Hahn, B. H. & other authors (2002). Diversity considerations in HIV-1 vaccine selection. Science 296, 2354-2360.
9. Gray, E. S., Meyers, T., Gray, G., Montefiori, D. C. & Morris, L. (2006). Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med 3, e255.
10. Guan, Y., Sajadi, M. M., Kamin-Lewis, R., Fouts, T. R., Dimitrov, A., Zhang, Z., Redfield, R. R., DeVico, A. L., Gallo, R. C. & other authors (2009). Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci U S A 106, 3952-3957.
11. Hemelaar, J., Gouws, E., Ghys, P. D. & Osmanov, S. (2006). Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20, W13-W23.
12. Karlsson Hedestam, G. B., Fouchier, R. A., Phogat, S., Burton, D. R., Sodroski, J. & Wyatt, R. T. (2008). The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6, 143-155.
13. Kostrikis, L. G., Cao, Y., Ngai, H., Moore, J. P. & Ho, D. D. (1996). Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 70, 445-458.
14. Labrijn, A. F., Poignard, P., Raja, A., Zwick, M. B., Delgado, K., Franti, M., Binley, J., Vivona, V., Grundner, C. & other authors (2003). Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77, 10557-10565.
15. Li, Y., Migueles, S. A., Welcher, B., Svehla, K., Phogat, A., Louder, M. K., Wu, X., Shaw, G. M., Connors, M. & other authors (2007). Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13, 1032-1034.
16. Li, Y., Svehla, K., Louder, M. K., Wycuff, D., Phogat, S., Tang, M., Migueles, S. A., Wu, X., Phogat, A. & other authors (2009). Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 83, 1045-1059.
17. Malim, M. H. & Emerman, M. (2001). HIV-1 sequence variation: drift, shift, and attenuation. Cell 104, 469-472.
18. Mascola, J. R., D'Souza, P., Gilbert, P., Hahn, B. H., Haigwood, N. L., Morris, L., Petropoulos, C. J., Polonis, V. R., Sarzotti, M. & other authors (2005). Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79, 10103-10107.
19. McCutchan, F. E. (2000). Understanding the genetic diversity of HIV-1. AIDS 14 (Suppl. 3), S31-S44.
20. McKnight, A. & Aasa-Chapman, M. M. (2007). Clade specific neutralising vaccines for HIV: an appropriate target? Curr HIV Res 5, 554-560.
21. Moog, C., Fleury, H. J. A., Pellegrin, I., Kirn, A. & Aubertin, A. M. (1997). Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 71, 3734-3741.
22. Moore, J. P., Cao, Y., Qing, L., Sattentau, Q. J., Pyati, J., Koduri, R., Robinson, J., Barbas, C. F., III, Burton, D. R. & other authors (1995). Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 69, 101-109.
23. Moore, J. P., Parren, P. W. & Burton, D. R. (2001). Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol 75, 5721-5729.
24. Pantaleo, G. & Koup, R. A. (2004). Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 10, 806-810.
25. Petropoulos, C. J., Parkin, N. T., Limoli, K. L., Lie, Y. S., Wrin, T., Huang, W., Tian, H., Smith, D., Winslow, G. A. & other authors (2000). A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44, 920-928.
26. Piantadosi, A., Panteleeff, D., Blish, C. A., Baeten, J. M., Jaoko, W., McClelland, R. S. & Overbaugh, J. (2009). HIV-1 neutralizing antibody breadth is affected by factors early in infection, but does not influence disease progression. J Virol 83, 10269-10274.
27. Quakkelaar, E. D., van Alphen, F. P., Boeser-Nunnink, B. D., van Nuenen, A. C., Pantophlet, R. & Schuitemaker, H. (2007). Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. J Virol 81, 8533-8542.
28. Richman, D. D., Wrin, T., Little, S. J. & Petropoulos, C. J. (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100, 4144-4149.
29. Sather, D. N., Armann, J., Ching, L. K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X., Wood, B., Self, S. & other authors (2009). Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83, 757-769.
30. Scheid, J. F., Mouquet, H., Feldhahn, N., Seaman, M. S., Velinzon, K., Pietzsch, J., Ott, R. G., Anthony, R. M., Zebroski, H. & other authors (2009). Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636-640.
31. Schweighardt, B., Liu, Y., Huang, W., Chappey, C., Lie, Y. S., Petropoulos, C. J. & Wrin, T. (2007). Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J Acquir Immune Defic Syndr 46, 1-11.
32. Shankarappa, R., Margolick, J. B., Gange, S. J., Rodrigo, A. G., Upchurch, D., Farzadegan, H., Gupta, P., Rinaldo, C. R., Learn, G. H. & other authors (1999). Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73, 10489-10502.
33. Simek, M. D., Rida, W., Priddy, F. H., Pung, P., Carrow, E., Laufer, D. S., Lehrman, J. K., Boaz, M., Tarragona-Fiol, T. & other authors (2009). HIV-1 elite neutralizers: individuals with broad and potent neutralizing activity identified using a high throughput neutralization assay together with an analytical selection algorithm. J Virol 83, 7337-7348.
34. Stebbing, J. & Moyle, G. (2003). The clades of HIV: their origins and clinical significance. AIDS Rev 5, 205-213.
35. Taylor, B. S., Sobieszczyk, M. E., McCutchan, F. E. & Hammer, S. M. (2008). The challenge of HIV-1 subtype diversity. N Engl J Med 358, 1590-1602.
36. van Gils, M. J., Euler, Z., Schweighardt, B., Wrin, T. & Schuitemaker, H. (2010). Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS (in press). doi:10.1097/ QAD.0b013e32833243e7.
37. van Griensven, G. J., de Vroome, E. M., Goudsmit, J. & Coutinho, R. A. (1989). Changes in sexual behavior and the fall in incidence of HIV infection among homosexual men. BMJ 298, 218-221.
38. Walker, B. D. & Burton, D. R. (2008). Toward an AIDS vaccine. Science 320, 760-764.
39. Walker, L. M., Phogat, S. K., Chan-Hui, P. Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S. & other authors (2009). Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289.
40. Webster, R. G., Bean, W. J., Gorman, O. T., Chambers, T. M. & Kawaoka, Y. (1992). Evolution and ecology of influenza A viruses. Microbiol Rev 56, 152-179.